Evidence map›Paper›PMID 36007554›Full record

ArticleAmerican journal of ophthalmology2022

Baseline Microperimetry and OCT in the RUSH2A Study: Structure-Function Association and Correlation With Disease Severity.

Eleonora M Lad, Jacque L Duncan, Wendi Liang, Maureen G Maguire, Allison R Ayala, Isabelle Audo, David G Birch, Joseph Carroll, Janet K Cheetham, Todd A Durham and 16 more

Open access · greenAbstract read
In one paragraph

Article in American journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Long-term natural history of ellipsoid zone width inThe British journal of ophthalmology · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 15 institutions in 4 countries.

Eleonora M LadFrom the Department of Ophthalmology, Duke University Medical Center Durham, North Carolina, USA.
Jacque L DuncanDepartment of Ophthalmology, University of California, San Francisco, California, USA.
Wendi LiangJaeb Center for Health Research, Tampa, Florida, USA.
Maureen G MaguireJaeb Center for Health Research, Tampa, Florida, USA.
Allison R AyalaJaeb Center for Health Research, Tampa, Florida, USA. Electronic address: ffbcorrespauth@jaeb.org.
Isabelle AudoInstitut de la Vision, Sorbonne Université, INSERM, CNRS, Paris, France; Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, INSERM-DGOS CIC1423, Paris, France.
David G BirchRetina Foundation of the Southwest, Dallas, Texas, USA.
Joseph CarrollMedical College of Wisconsin, Milwaukee, Wisconsin, USA.
Janet K CheethamFoundation Fighting Blindness, Columbia, Maryland, USA.
Todd A DurhamFoundation Fighting Blindness, Columbia, Maryland, USA.
Abigail T FahimKellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA.
Jessica LooDepartment of Biomedical Engineering, Duke University, Durham, North Carolina, USA.
Zengtian DengDepartment of Biomedical Engineering, Duke University, Durham, North Carolina, USA.
Dibyendu MukherjeeDepartment of Biomedical Engineering, Duke University, Durham, North Carolina, USA.
Elise HeonUniversity of Toronto and Hospital for Sick Children, Toronto, Ontario, Canada.
Robert B HufnagelNational Eye Institute, Bethesda, Maryland, USA.
Bin GuanNational Eye Institute, Bethesda, Maryland, USA.
Alessandro IannacconeFrom the Department of Ophthalmology, Duke University Medical Center Durham, North Carolina, USA.
Glenn J JaffeFrom the Department of Ophthalmology, Duke University Medical Center Durham, North Carolina, USA.
Christine N KayVitreoretinal Associates, Gainesville, Florida, USA.
Michel MichaelidesMoorfields Eye Hospital and UCL Institute of Ophthalmology (M.M.), London, United Kingdom.
Mark E PennesiCasey Eye Institute, Oregon Health & Science University, Portland, Oregon, USA.
Ajoy VincentUniversity of Toronto and Hospital for Sick Children, Toronto, Ontario, Canada.
Christina Y WengBaylor College of Medicine, Houston, Texas.
Sina FarsiuFrom the Department of Ophthalmology, Duke University Medical Center Durham, North Carolina, USA; Department of Biomedical Engineering, Duke University, Durham, North Carolina, USA.
Foundation Fighting Blindness Consortium Investigator Group
Duke University · USDuke Medical Center · USJaeb Center for Health Research · USFoundation Fighting Blindness · USNational Eye Institute · USUniversity of Toronto · CABaylor College of Medicine · USCentre National de la Recherche Scientifique · FRMedical College of Wisconsin · USMoorfields Eye Hospital NHS Foundation Trust · GBOregon Health & Science University · USRetina Foundation of the Southwest · USRetina Vitreous Associates of Florida · USUniversity of California, San Francisco · USW.K. Kellogg Foundation · US

Funding

VISION RESEARCHP30EY005722 · NEI · DUKE UNIVERSITY · PI Vadim Y Arshavsky · 1985 to 2026
$19.3M
Rapid-Prototyping and Design CoreP30EY002162 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NAIR, KAYARAT SAIDAS · 1985 to 2024
$16.8M
MEASURES OF HUMAN RECEPTOR AND POST RECEPTOR ACTIVITYR01EY009076 · NEI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI BIRCH, DAVID G, HOOD, DONALD C. · 1991 to 2021
$8.3M
Michigan Vision Clinician Scientist Development ProgramK12EY022299 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Abigail Fahim, DAVID N ZACKS · 2013 to 2026
$6.3M
Investigating Membrane Trafficking Deficits in ChoroideremiaK08EY032991 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FAHIM, ABIGAIL · 2021 to 2023
$713k
Foundation Fighting Blindness RUSH2A - CONSORTIUM - 2016NEI NIH HHS K08 EY032991NEI NIH HHS K12 EY022299NEI NIH HHS P30 EY002162NEI NIH HHS P30 EY005722NEI NIH HHS R01 EY009076
6 · The paper itself

Abstract

purposeTo investigate baseline mesopic microperimetry (MP) and spectral domain optical coherence tomography (OCT) in the Rate of Progression in USH2A-related Retinal Degeneration (RUSH2A) study.

designNatural history study

methodsSetting: 16 clinical sites in Europe and North AmericaStudy Population: Participants with Usher syndrome type 2 (USH2) (N = 80) or autosomal recessive nonsyndromic RP (ARRP) (N = 47) associated with biallelic disease-causing sequence variants in USH2AObservation Procedures: General linear models were used to assess characteristics including disease duration, MP mean sensitivity and OCT intact ellipsoid zone (EZ) area. The associations between mean sensitivity and EZ area with other measures, including best corrected visual acuity (BCVA) and central subfield thickness (CST) within the central 1 mm, were assessed using Spearman correlation coefficients.

main outcome measuresMean sensitivity on MP; EZ area and CST on OCT.

resultsAll participants (N = 127) had OCT, while MP was obtained at selected sites (N = 93). Participants with Usher syndrome type 2 (USH2, N = 80) and nonsyndromic autosomal recessive Retinitis Pigmentosa (ARRP, N = 47) had the following similar measurements: EZ area (median (interquartile range [IQR]): 1.4 (0.4, 3.1) mm

conclusionsLonger disease duration correlated with more severe retinal structure and function abnormalities, and there were associations between MP and OCT metrics. Monitoring changes in retinal structure-function relationships during disease progression will provide important insights into disease mechanism in USH2A-related retinal degeneration.

Indexed as

Retinal DegenerationUsher SyndromesHumansSeverity of Illness IndexTomography, Optical CoherenceVisual AcuityVisual Field Tests

Identifiers

PMID36007554
PMCPMC9712171
OpenAlexW4292633166

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.